Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Ranibizumab is an anti-VEGF medicine injected into the eye to treat certain retinal diseases. VEGF stands for vascular endothelial growth factor, a protein that can cause abnormal blood vessel growth and leakage. By blocking VEGF, ranibizumab can reduce retinal swelling, bleeding, and fluid. It is sold under names such as Lucentis, with biosimilar versions also available.
read more about ranibizumab ...Ranibizumab binds to VEGF and lowers its activity inside the eye. This helps reduce abnormal vessel growth and leakage in the retina. Less fluid in the macula can help stabilize or improve vision in some patients. The medicine is given as an intravitreal injection because it needs to reach the back of the eye.
Ranibizumab is used for wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, macular edema after retinal vein occlusion, and myopic choroidal neovascularization. These conditions involve abnormal blood vessels, retinal swelling, or leakage that can threaten central vision. The specific dose and schedule depend on the condition being treated. An ophthalmologist monitors the retina with exams and imaging during treatment.
Before the injection, the eye is numbed and cleaned with antiseptic to lower discomfort and infection risk. The doctor places a small amount of ranibizumab into the vitreous with a fine needle. Treatment can require repeated injections because VEGF-related leakage can return. Follow-up visits help decide whether to continue, adjust, space, or switch treatment.
Temporary redness, irritation, floaters, or a gritty feeling can happen after the injection. Rare but serious eye risks include infection inside the eye, retinal detachment, inflammation, bleeding, and increased eye pressure. Anti-VEGF medicines also carry warnings about possible arterial thromboembolic events, such as stroke or heart attack, though these events are uncommon. Patients should report eye pain, worsening redness, sudden vision loss, light sensitivity, or new severe floaters right away.
Yes, Lucentis is the original medicine name for ranibizumab. Biosimilar ranibizumab products are also available for selected retinal conditions.
No, ranibizumab is not a steroid. It is an anti-VEGF medicine that targets abnormal blood vessel growth and leakage in the retina.
No, ranibizumab does not cure wet age-related macular degeneration. It can help control leakage and swelling, but ongoing monitoring and repeat injections can be needed.
The schedule depends on the diagnosis, product, and response to treatment. Some patients start with monthly injections before the doctor adjusts the interval based on retinal findings.
Ranibizumab Injection. MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a607044.html. Date Accessed June 3, 2026.
Ranibizumab Intraocular Route. Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/ranibizumab-intraocular-route/description/drg-20070855. Date Accessed June 3, 2026.
Ranibizumab. StatPearls, NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK544362/. Date Accessed June 3, 2026.
Label: LUCENTIS Ranibizumab Injection, Solution. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de4e66cc-ca05-4dc9-8262-e00e9b41c36d. Date Accessed June 3, 2026.
Ranibizumab Injection. Cleveland Clinic. https://my.clevelandclinic.org/health/drugs/20659-ranibizumab-injection. Date Accessed June 3, 2026.